You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Upadacitinib for previously treated moderately to severely active Crohn’s disease

  • Technology appraisal guidance
  • Reference number: TA905
  • Published:  21 June 2023
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 141 KB)

    Published:
    18 May 2023
  • Register of interests (PDF 157 KB)

    Published:
    21 June 2023

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 179 KB)

    Published:
    18 May 2023
  • Committee papers (PDF 4.75 MB)

    Published:
    18 May 2023
  • Public committee slides (PDF 1.29 MB)

    Published:
    18 May 2023

Invitation to participate

  • Final scope (PDF 191 KB)

    Published:
    02 August 2022
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 273 KB)

    Published:
    02 August 2022
  • Equality impact assessment (Scoping) (PDF 118 KB)

    Published:
    03 August 2022
  • Final stakeholder list (PDF 134 KB)

    Published:
    03 August 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 210 KB)

    Published:
    23 March 2022
  • Draft matrix post referral (PDF 146 KB)

    Published:
    23 March 2022
Back to top